121 related articles for article (PubMed ID: 35234527)
1. New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma.
Puzyrenko A; Cortina CS; Jorns JM
Int J Surg Pathol; 2022 Oct; 30(7):728-733. PubMed ID: 35234527
[TBL] [Abstract][Full Text] [Related]
2. Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens.
Ren S; Klump W
Arch Pathol Lab Med; 2019 Jun; 143(6):677-682. PubMed ID: 29688031
[TBL] [Abstract][Full Text] [Related]
3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
4. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
5. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
Ramalingam P; Masand RP; Euscher ED; Malpica A
Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
[TBL] [Abstract][Full Text] [Related]
6. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Boyd C; McCluggage WG
Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
[TBL] [Abstract][Full Text] [Related]
7. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
8. Unexpected PAX8 Immunoreactivity in Metastatic High-grade Breast Cancer.
Kilgore MR; Bosch DE; Adamson KH; Swanson PE; Dintzis SM; Rendi MH
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):637-643. PubMed ID: 30358609
[TBL] [Abstract][Full Text] [Related]
9. Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
Mirsadraei L; Hodkoff A; Jones K; Shabaik A; Kader AK; Saenz CC; Montironi R; Tacha DE; Fadare O; Hansel DE
Arch Pathol Lab Med; 2018 Feb; 142(2):168-177. PubMed ID: 28795841
[TBL] [Abstract][Full Text] [Related]
10. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
11. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
[TBL] [Abstract][Full Text] [Related]
13. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
14. The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer.
El-Arabey AA; Abdalla M
Hum Cell; 2022 Jul; 35(4):1298-1300. PubMed ID: 35459984
[No Abstract] [Full Text] [Related]
15. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.
Zhao L; Guo M; Sneige N; Gong Y
Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458
[TBL] [Abstract][Full Text] [Related]
16. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
17. Carcinosarcoma arising from high-grade serous carcinoma of the ovary without estrogen receptor, WT-1, and PAX8 immunoreactivity.
Harada N; Nobuhara I; Haruta N; Higashiura Y; Fujii H; Yamao K; Shimada K
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):110-114. PubMed ID: 35181017
[TBL] [Abstract][Full Text] [Related]
18. Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.
Na K; Woo HY; DO SI; Kim SW
In Vivo; 2022; 36(1):473-481. PubMed ID: 34972751
[TBL] [Abstract][Full Text] [Related]
19. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
20. PAX8 Expression in Breast Cancer.
Lu S; Yakirevich E; Hart J; Wang L; Wang Y
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):293-298. PubMed ID: 33208672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
